PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas

PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas

Blog Article

Soft-tissue sarcomas (STS) are a group of rare, heterogeneous, and aggressive tumors, with high metastatic risk and relatively few efficient systemic therapies.In the quest for new treatments, the immune system Course a pied - Femme - Sous-vetements - Brief represents an attractive therapeutic target.Recently, PD1/PDL1 inhibitors showed very promising results in patients with solid tumors.

PDL1 expression has been rarely studied in STS, in small series only, by using immunohistochemistry (IHC), and with non-concordant prognostic implications.Here, we have analyzed PDL1 mRNA expression in 758 clinical STS samples retrospectively profiled using DNA microarrays and RNAseq, and searched for correlations with clinicopathological variables including metastasis-free survival (MFS) after surgery.PDL1 expression was heterogeneous across the samples.

PDL1-high samples (41%) were more frequently leiomyosarcomas and liposarcomas, and showed more frequently a complex genetic profile and a high-risk CINSARC signature.No correlation existed with other clinicopathological features such as tumor site, depth, and pathological tumor grade and size.In multivariate prognostic analysis, the PDL1-high class was associated with shorter MFS, independently of the pathological type and the CINSARC signature.

Analysis of correlations with biological factors suggested the existence in tumors of the PDL1-high class of a strong and efficient cytotoxic T-cell response, however associated with some degree of T-cell exhaustion and negative regulation.In conclusion, we show that PDL1 expression refines the prediction of metastatic relapse in operated localized STS, and that PD1/PDL1 blockade holds potential to improve patient survival by reactivating inhibited magnets T cells to increase the antitumor immune in PDL1-high tumors.